KalVista Pharmaceuticals, Inc. (KALV) Stock Profile — Insider Trades & Financials

Revenue$35.4M

Net Income$49.4M

EPS$-2.97

Market Cap$987.1M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Benjamin Palleiko

CEO & Executive Director

KalVista Pharmaceuticals, Inc., a biopharmaceutical company, develops oral therapies for individuals for rare diseases with unmet needs. Its lead product candidate is EKTERLY, a fast-acting potent inhibitor of plasma kallikrein for the treatment of acute attacks of hereditary angioedema (HAE). The company is also developing is developing an orally disintegrating tablet formulation; KONFIDENT-KID for pediatric use with HAE; KONFIDENT; and KONFIDENT-S to evaluate sebetralstat and ODT formulation in adolescent and adult patients. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts.

Employees: 275
Headquarters: Framingham, Massachusetts, United States
Website: www.kalvista.com

⚡

Core Efficiency

ROE?

-1821.84%

ROA?

14.73%

D/E Ratio?

-124.71

Op. Margin?

120.69%

📊

Profitability Ratios

Net Margin?

139.57%

Loading company sections...

KalVista Pharmaceuticals, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness